NCT01578304View on ClinicalTrials.gov

Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder

PHASE4CompletedINTERVENTIONAL
Enrollment

207

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Overactive Bladder
Interventions
DRUG

Imidafenacin

Tablet, 12 weeks twice daily

DRUG

Fesoterodine

Tablet, 12 weeks once daily

Trial Locations (1)

135-710

Samsung Medical Center, Seoul

Sponsors

Lead Sponsor

LG Life Sciences
All Listed Sponsors
collaborator

Kyorin Pharmaceutical Co.,Ltd

INDUSTRY

lead

LG Life Sciences

INDUSTRY